A plant extract composition capable of promoting blood circulation and its application

Abstract

The present invention relates to a plant extract composition capable of promoting blood circulation and its application, and belongs to the technical field of plant extract compositions. The plant extract composition disclosed in the present invention comprises the following raw materials: Rooibos tea extract, scutellaria root extract, modified chlorogenic acid, astragalus extract, and angelica extract. Rooibos tea extract can reduce myocardial damage and oxidative stress, while scutellaria root extract can reduce myocardial inflammation damage by inhibiting myocardial cell inflammation, and the two cooperate to protect the heart; modified chlorogenic acid has the function of protecting blood vessels, while the surface modification of amylopectin makes it more hydrophilic and stable; astragalus extract and angelica extract can reduce the viscosity of blood and have the effect of promoting blood circulation. The plant extract composition formed by the above components of the present invention has the functions of invigorating qi and promoting blood circulation, protecting blood vessels and the heart, and thus better promoting blood circulation.

Description

Technical Field

[0001] The invention belongs to the technical field of plant extract compositions and relates to a plant extract composition capable of promoting blood circulation and an application thereof. Background Art

[0002] Blood circulation is a complete closed circulatory system, with the heart as the center, connected to organs and tissues throughout the body through blood vessels, and blood circulates in it. The main function of blood circulation is to transport substances in the body. Once blood circulation stops, the organs and tissues of the body will suffer from metabolic disorders due to the loss of normal substance transport. At the same time, the structure and function of some important organs in the body will be damaged, especially the cerebral cortex, which is sensitive to hypoxia. As long as the blood circulation in the brain stops for 3 to 4 minutes, people will lose consciousness. If the blood circulation stops for 4 to 5 minutes, more than half of the people will suffer permanent brain damage. If it stops for 10 minutes, even if not all intelligence is destroyed, most of it will be destroyed. The blood circulating in the human body can transport nutrients to all parts of the body and collect waste in the human body and excrete it out of the body. When blood flows out of the heart, it transports nutrients and oxygen to all parts of the body; when blood flows back to the heart, it transports carbon dioxide and other wastes produced by the body to the excretory organs and excretes them out of the body.

[0003] Patent CN100431537C discloses a blood flow improver, which relates to a blood flow improver, a blood circulation promoter, and a cerebrovascular disorder improver with one or more selected from chlorogenic acids, caffeic acid, ferulic acid, or pharmaceutically acceptable salts thereof as active ingredients. The blood flow improver prepared by the invention can be effectively used for the prevention and treatment of all poor blood circulation caused by living environment, seasonal changes, or aging, and can be used as a medicine or health product. Chlorogenic acid directly added to the formula of the invention plays a major role in blood circulation, but the ortho-diphenolic hydroxyl group in the molecular structure of chlorogenic acid is easily oxidized to reduce its medicinal effect, and its instability and poor solubility in water have great limitations in drug research and development. Therefore, the present invention provides a specific solution to this problem. Summary of the invention

[0004] The present invention relates to a plant extract composition capable of promoting blood circulation and its application, and belongs to the technical field of plant extract compositions. The plant extract composition disclosed in the present invention comprises the following raw materials: rooibos tea extract, scutellaria root extract, modified chlorogenic acid, astragalus extract, and angelica extract. Rooibos tea extract can reduce myocardial damage and oxidative stress, while scutellaria root extract can protect the heart by inhibiting the inflammatory response of myocardial cells and reducing myocardial inflammatory damage; modified chlorogenic acid can protect blood vessels, while the surface modification of amylopectin makes it more hydrophilic and stable; astragalus extract and angelica extract can reduce the viscosity of blood and have the effect of promoting blood circulation. The plant extract composition formed by the above components of the present invention has the effects of invigorating qi and promoting blood circulation, protecting blood vessels and the heart, and thus better promoting blood circulation.

[0005] The purpose of the present invention can be achieved through the following technical solutions:

[0006] A plant extract composition capable of promoting blood circulation comprises the following raw materials in parts by weight: 8-15 parts of Rooibos tea extract, 8-15 parts of scutellaria root extract, 10-20 parts of modified chlorogenic acid, 10-20 parts of astragalus extract, and 10-20 parts of angelica extract.

[0007] Furthermore, the preparation method of the Rooibos tea extract is as follows: the Rooibos tea is dried and crushed into powder, an ethanol solution is added for ultrasonication, the filter residue is removed by filtration, the filtrate is concentrated, and the powder is dried to obtain the Rooibos tea extract, the mass fraction of the ethanol solution is 50%, the solid-liquid ratio of the powder to the ethanol solution is 1:1.25-1.5 g / mL, and the ultrasonic time and temperature are 60-90 min and 70-80 ° C, respectively.

[0008] Furthermore, the preparation method of the scutellaria root extract is: scutellaria root powder is mixed with 8 times the mass of ethanol solution, reflux extraction is performed 3 times, each time for 2 hours, the obtained solutions are combined and concentrated under reduced pressure to form a concentrated solution, and then petroleum ether with an equal volume to the concentrated solution is added for extraction, the extract is concentrated, and dried to form a powder, which is the scutellaria root extract, and the mass fraction of the ethanol solution is 70%.

[0009] Furthermore, the preparation method of the modified chlorogenic acid comprises the following steps:

[0010] A1: crush the Eucommia leaves, add ethanol solution, perform ultrasonic treatment, filter to remove the residue, concentrate the filtrate, and dry to form powder;

[0011] A2: Put the powder and amylopectin into acetic acid solution at the same time and stir to mix, then add triethylamine and mix, filter and wash the residue with distilled water until it is neutral, and dry at low temperature to obtain modified chlorogenic acid.

[0012] Furthermore, in step A1, the solid-liquid ratio of Eucommia ulmoides leaves to the ethanol solution is 1:20-30 g / mL, wherein the mass fraction of the ethanol solution is 50-60%.

[0013] Furthermore, the time and temperature of the ultrasonic treatment in step A1 are 30-60 min and 50-60° C., respectively, and the power of the ultrasound is 400-800 w.

[0014] Furthermore, in step A2, the mass ratio of the powder, pullulan, acetic acid solution and triethylamine is 1:1:3-4:0.13-0.15, and the mass fraction of the acetic acid solution is 2-3%.

[0015] Furthermore, in the step A2, the mixing time and temperature are 1-3h and 60-80°C respectively, and the low-temperature drying temperature is 40-45°C.

[0016] Beneficial effects of the present invention:

[0017] 1. Rooibos tea extract reduces the level of lipid peroxidation products and fatty acid synthase activity in heart tissue, thereby reducing myocardial damage and oxidative stress. At the same time, Scutellaria root extract inhibits myocardial cell inflammatory response and reduces myocardial inflammatory damage. The two work together to protect the heart.

[0018] 2. Chlorogenic acid has the functions of scavenging free radicals and anti-oxidation, inhibiting endothelial cell apoptosis caused by hydrogen peroxide, and playing a good protective role on blood vessels by inhibiting the damage of vascular endothelial cells caused by lysophosphatidylcholine. The present invention uses amylopectin and chlorogenic acid to undergo an esterification reaction under the catalysis of triethylamine, which not only retains the original properties of chlorogenic acid, but also makes the modified chlorogenic acid hydrophilic, and stably exists in the solution without precipitation;

[0019] 3. The plant extract composition provided by the present invention has the effects of invigorating qi and activating blood circulation, protecting blood vessels and the heart, and thus better promoting blood circulation. DETAILED DESCRIPTION

[0020] In order to further illustrate the technical means and effects adopted by the present invention to achieve the predetermined invention purpose, the specific implementation methods, structures, features and effects of the present invention are described in detail below in combination with embodiments.

[0021] Example 1

[0022] A plant extract composition capable of promoting blood circulation comprises the following raw materials in parts by weight: 8 parts of Rooibos tea extract, 8 parts of scutellaria root extract, 10 parts of modified chlorogenic acid, 10 parts of astragalus extract, and 10 parts of angelica extract.

[0023] The preparation method of the Rooibos tea extract is as follows: Rooibos tea is dried and crushed into powder, an ethanol solution is added for ultrasonic treatment, the filter residue is removed by filtration, the filtrate is concentrated, and the powder is dried to obtain the Rooibos tea extract, the mass fraction of the ethanol solution is 50%, the solid-liquid ratio of the powder to the ethanol solution is 1:1.25 g / mL, and the ultrasonic time and temperature are 60 min and 70° C., respectively.

[0024] The preparation method of the scutellaria root extract is as follows: scutellaria root powder is mixed with 8 times the mass of ethanol solution, reflux extraction is performed 3 times, each time for 2 hours, the obtained solutions are combined and concentrated under reduced pressure to form a concentrated solution, and then petroleum ether with an equal volume to the concentrated solution is added for extraction, the extract is concentrated, and dried to form a powder, which is the scutellaria root extract, and the mass fraction of the ethanol solution is 70%.

[0025] The preparation method of the modified chlorogenic acid comprises the following steps:

[0026] A1: crush the Eucommia ulmoides leaves, add ethanol solution, perform ultrasonic treatment, filter to remove the residue, compress the filtrate, and dry to form powder;

[0027] A2: Put the powder and amylopectin into acetic acid solution at the same time and stir to mix, then add triethylamine and mix, filter and wash the residue with distilled water until it is neutral, and dry at low temperature to obtain modified chlorogenic acid.

[0028] In the step A1, the solid-liquid ratio of Eucommia ulmoides leaves to the ethanol solution is 1:20 g / mL, wherein the mass fraction of the ethanol solution is 50%.

[0029] The time and temperature of the ultrasonic treatment in step A1 are 30 min and 50° C., respectively, and the power of the ultrasonic treatment is 400 w.

[0030] In the step A2, the mass ratio of the powder, pullulan, acetic acid solution and triethylamine is 1:1:3:0.13, and the mass fraction of the acetic acid solution is 2%.

[0031] The mixing time and temperature in step A2 are 1 hour and 60° C. respectively, and the low-temperature drying temperature is 40° C.

[0032] The plant extract composition can be an oral liquid, and the content of the plant extract composition in the oral liquid is 30%.

[0033] The astragalus extract was purchased from: Astragalus Extract / Ruierli Biotechnology, the angelica extract was purchased from: Angelica Extract / Youshuo Biotechnology, and the pullulan was purchased from: pullulan / Huaxiang-DW3432.

[0034] Example 2

[0035] A plant extract composition capable of promoting blood circulation, comprising the following raw materials in parts by weight: 12 parts of Rooibos tea extract, 12 parts of scutellaria root extract, 15 parts of modified chlorogenic acid, 15 parts of astragalus extract, and 15 parts of angelica extract.

[0036] The preparation method of the Rooibos tea extract is as follows: Rooibos tea is dried and crushed into powder, an ethanol solution is added for ultrasonic treatment, the filter residue is removed by filtration, the filtrate is concentrated, and the powder is dried to obtain the Rooibos tea extract, the mass fraction of the ethanol solution is 50%, the solid-liquid ratio of the powder to the ethanol solution is 1:1.35 g / mL, and the ultrasonic time and temperature are 75 min and 75° C., respectively.

[0037] The preparation method of the scutellaria root extract is as follows: scutellaria root powder is mixed with 8 times the mass of ethanol solution, reflux extraction is performed 3 times, each time for 2 hours, the obtained solutions are combined and concentrated under reduced pressure to form a concentrated solution, and then petroleum ether with an equal volume to the concentrated solution is added for extraction, the extract is concentrated, and dried to form a powder, which is the scutellaria root extract, and the mass fraction of the ethanol solution is 70%.

[0038] The preparation method of the modified chlorogenic acid comprises the following steps:

[0039] A1: crush the Eucommia leaves, add ethanol solution, perform ultrasonic treatment, filter to remove the residue, concentrate the filtrate, and dry to form powder;

[0040] A2: Put the powder and amylopectin into acetic acid solution at the same time and stir to mix, then add triethylamine and mix, filter and wash the residue with distilled water until it is neutral, and dry at low temperature to obtain modified chlorogenic acid.

[0041] In the step A1, the solid-liquid ratio of Eucommia ulmoides leaves to the ethanol solution is 1:25 g / mL, wherein the mass fraction of the ethanol solution is 55%.

[0042] The time and temperature of the ultrasonic treatment in step A1 are 45 min and 55° C., respectively, and the power of the ultrasonic treatment is 600 w.

[0043] In the step A2, the mass ratio of the powder, pullulan, acetic acid solution and triethylamine is 1:1:3.5:0.14, and the mass fraction of the acetic acid solution is 2.5%.

[0044] The mixing time and temperature in step A2 are 2 hours and 70° C. respectively, and the low-temperature drying temperature is 40° C.

[0045] The plant extract composition can be an oral liquid, and the content of the plant extract composition in the oral liquid is 30%.

[0046] The astragalus extract was purchased from: Astragalus Extract / Ruierli Biotechnology, the angelica extract was purchased from: Angelica Extract / Youshuo Biotechnology, and the pullulan was purchased from: pullulan / Huaxiang-DW3432.

[0047] Example 3

[0048] A plant extract composition capable of promoting blood circulation, comprising the following raw materials in parts by weight: 15 parts of Rooibos tea extract, 15 parts of scutellaria root extract, 20 parts of modified chlorogenic acid, 20 parts of astragalus extract, and 20 parts of angelica extract.

[0049] The preparation method of the Rooibos tea extract is as follows: Rooibos tea is dried and crushed into powder, an ethanol solution is added for ultrasonic treatment, the filter residue is removed by filtration, the filtrate is concentrated, and the powder is dried to obtain the Rooibos tea extract, the mass fraction of the ethanol solution is 50%, the solid-liquid ratio of the powder to the ethanol solution is 1:1.5 g / mL, and the ultrasonic time and temperature are 90 min and 80° C., respectively.

[0050] The preparation method of the scutellaria root extract is as follows: scutellaria root powder is mixed with 8 times the mass of ethanol solution, reflux extraction is performed 3 times, each time for 2 hours, the obtained solutions are combined and concentrated under reduced pressure to form a concentrated solution, and then petroleum ether with an equal volume to the concentrated solution is added for extraction, the extract is concentrated, and dried to form a powder, which is the scutellaria root extract, and the mass fraction of the ethanol solution is 70%.

[0051] The preparation method of the modified chlorogenic acid comprises the following steps:

[0052] A1: crush the Eucommia ulmoides leaves, add ethanol solution, perform ultrasonic treatment, filter to remove the residue, concentrate the filtrate, and dry to form powder;

[0053] A2: Put the powder and amylopectin into acetic acid solution at the same time and stir to mix, then add triethylamine and mix, filter and wash the residue with distilled water until it is neutral, and dry at low temperature to obtain modified chlorogenic acid.

[0054] In the step A1, the solid-liquid ratio of Eucommia ulmoides leaves to the ethanol solution is 1:30 g / mL, wherein the mass fraction of the ethanol solution is 60%.

[0055] The time and temperature of the ultrasonic treatment in step A1 are 60 min and 60° C., respectively, and the power of the ultrasonic treatment is 800 w.

[0056] In the step A2, the mass ratio of the powder, pullulan, acetic acid solution and triethylamine is 1:1:4:0.15, and the mass fraction of the acetic acid solution is 3%.

[0057] The mixing time and temperature in step A2 are 3 hours and 80° C. respectively, and the low-temperature drying temperature is 45° C.

[0058] The plant extract composition can be an oral liquid, and the content of the plant extract composition in the oral liquid is 30%.

[0059] The astragalus extract was purchased from: Astragalus Extract / Ruierli Biotechnology, the angelica extract was purchased from: Angelica Extract / Youshuo Biotechnology, and the pullulan was purchased from: pullulan / Huaxiang-DW3432.

[0060] Comparative Example 1

[0061] On the basis of Example 2, a plant extract composition for promoting blood circulation is provided, which comprises the following raw materials in parts by weight: 12 parts of Rooibos tea extract, 12 parts of Scutellaria root extract, 15 parts of Eucommia leaf extract, 15 parts of Astragalus extract, and 15 parts of Angelica extract.

[0062] The preparation method of the Rooibos tea extract is as follows: Rooibos tea is dried and crushed into powder, an ethanol solution is added for ultrasonic treatment, the filter residue is removed by filtration, the filtrate is concentrated, and the powder is dried to obtain the Rooibos tea extract, the mass fraction of the ethanol solution is 50%, the solid-liquid ratio of the powder to the ethanol solution is 1:1.35 g / mL, and the ultrasonic time and temperature are 75 min and 75° C., respectively.

[0063] The preparation method of the scutellaria root extract is as follows: scutellaria root powder is mixed with 8 times the mass of ethanol solution, reflux extraction is performed 3 times, each time for 2 hours, the obtained solutions are combined and concentrated under reduced pressure to form a concentrated solution, and then petroleum ether with an equal volume to the concentrated solution is added for extraction, the extract is concentrated, and dried to form a powder, which is the scutellaria root extract, and the mass fraction of the ethanol solution is 70%.

[0064] The preparation method of the modified chlorogenic acid comprises the following steps:

[0065] A1: Crush the eucommia leaves, add ethanol solution, perform ultrasonic treatment, filter to remove the residue, concentrate the filtrate, and dry to obtain the eucommia leaf extract.

[0066] In the step A1, the solid-liquid ratio of Eucommia ulmoides leaves to the ethanol solution is 1:25 g / mL, wherein the mass fraction of the ethanol solution is 55%.

[0067] The time and temperature of the ultrasonic treatment in step A1 are 45 min and 55° C., respectively, and the power of the ultrasonic treatment is 600 w.

[0068] The plant extract composition can be an oral liquid, and the content of the plant extract composition in the oral liquid is 30%.

[0069] The purchasing source of the Astragalus extract is: Astragalus extract / Rui Er Li Biotechnology, and the purchasing source of the Angelica extract is: Angelica extract / You Shuo Biotechnology.

[0070] Comparative Example 2

[0071] On the basis of Example 2, the Rooibos tea extract and the Scutellaria baicalensis root extract in the plant extract composition were removed and replaced with an equal weight portion of modified chlorogenic acid. Other conditions were the same as in Example 2.

[0072] Comparative Example 3

[0073] On the basis of Example 2, the Rooibos tea extract in the plant extract composition was removed and replaced with an equal weight portion of Scutellaria baicalensis root extract, and other conditions were consistent with Example 2.

[0074] Comparative Example 4

[0075] On the basis of Example 2, the scutellaria root extract in the plant extract composition was removed and replaced with an equal weight portion of rooibos tea extract. Other conditions were the same as in Example 2.

[0076] Comparative Example 5

[0077] On the basis of Example 2, the modified chlorogenic acid in the plant extract composition was removed and replaced with 7 parts by weight of Rooibos tea extract and 8 parts by weight of Scutellaria baicalensis root extract. Other conditions were the same as in Example 2.

[0078] Comparative Example 6

[0079] On the basis of Example 2, the Astragalus extract and the Angelica extract in the plant extract composition were removed and replaced with an equal weight portion of modified chlorogenic acid. Other conditions were the same as in Example 2.

[0080] Performance Testing

[0081] 1. Select healthy rats and divide them into 10 groups, each with 20 rats. Use the oral solution prepared in Examples 1-3 and Comparative Examples 1-6 to gavage 0.5 mL of the rats in the corresponding groups once a day, which is regarded as the experimental group. A group of rats gavaged with 0.5 mL of normal saline is set as the control group. Test environment: The temperature is 21±2℃, rats can eat and drink freely, and the basic feed conditions are the same. The test is carried out after 7 consecutive weeks of gavage, as follows:

[0082] Three rats were randomly selected from each group, and their body weights were measured and recorded. They were anesthetized intraperitoneally with 10% chloral hydrate at a rate of 0.3% of their body weight. Blood was collected from the jugular vein and abdominal aorta of the rats for determination of hematological indices, namely, blood gas indices.

[0083] The above test results are shown in Table 1.

[0084] Table 1 Test results

[0085]

[0086] From the data analysis in Table 1, it can be seen that the PO of Examples 1-3 2 and SO 2 The content of PO is greater than that of comparative examples 1-6 and the control group. 2 The indicator is the oxygen partial pressure in the blood, which is an important indicator reflecting oxygen delivery and oxygen utilization. The higher the value, the better the blood circulation; SO 2 The index is the hemoglobin saturation in the blood, which is an important indicator reflecting the blood oxygen level. In Comparative Example 1, unmodified chlorogenic acid is used, and its stability is worse than that of the embodiment, and its effect on promoting blood circulation is weaker; Comparative Examples 2-6 lack any component of South African tea extract, scutellaria root extract, modified chlorogenic acid, astragalus extract, and angelica extract, and its effect on promoting blood circulation is reduced. The composition starts from the protection of the heart, blood vessels and blood, and the blood circulation effect is the best.

[0087] The above description is only a preferred embodiment of the present invention and does not limit the present invention in any form. Although the present invention has been disclosed as a preferred embodiment as above, it is not used to limit the present invention. Any technical personnel in this field can make some changes or modify the technical contents disclosed above into equivalent embodiments without departing from the scope of the technical solution of the present invention. However, any brief modifications, equivalent changes and modifications made to the above embodiments based on the technical essence of the present invention without departing from the content of the technical solution of the present invention are still within the scope of the technical solution of the present invention.

Claims

1. A plant extract composition capable of promoting blood circulation, characterized in that: The plant extract composition capable of promoting blood circulation is composed of the following raw materials in parts by weight: 8-15 parts of Rooibos tea extract, 8-15 parts of scutellaria root extract, 10-20 parts of modified chlorogenic acid, 10-20 parts of astragalus extract, and 10-20 parts of angelica extract; The preparation method of the Rooibos tea extract is as follows: Rooibos tea is dried and crushed into powder, an ethanol solution is added for ultrasonic treatment, the filter residue is removed by filtration, the filtrate is concentrated, and the powder is dried to obtain the Rooibos tea extract, the mass fraction of the ethanol solution is 50%, the solid-liquid ratio of the powder to the ethanol solution is 1:1.25-1.5 g / mL, and the ultrasonic time and temperature are 60-90 min and 70-80° C. respectively; The preparation method of the scutellaria root extract is as follows: scutellaria root powder is mixed with 8 times the mass of ethanol solution, reflux extraction is performed 3 times, each time for 2 hours, the obtained solutions are combined and concentrated under reduced pressure to form a concentrated solution, and then petroleum ether with the same volume as the concentrated solution is added for extraction, and the extract is concentrated and dried to form a powder, which is the scutellaria root extract, and the mass fraction of the ethanol solution is 70%; The preparation method of the modified chlorogenic acid comprises the following steps: A1: crush the Eucommia leaves, add ethanol solution, perform ultrasonic treatment, filter to remove the residue, and concentrate and dry the filtrate to form powder; The solid-liquid ratio of the eucommia leaves to the ethanol solution is 1:20-30 g / mL, wherein the mass fraction of the ethanol solution is 50-60%; the time and temperature of the ultrasonic treatment are 30-60 min and 50-60° C., respectively, and the power of the ultrasound is 400-800 w; A2: Put the powder and amylopectin into acetic acid solution at the same time and stir to mix, then add triethylamine to mix, filter and wash the residue with distilled water until it is neutral, and dry at low temperature to obtain modified chlorogenic acid; The mass ratio of the powder, pullulan, acetic acid solution and triethylamine is 1:1:3-4:0.13-0.15, and the mass fraction of the acetic acid solution is 2-3%; the mixing time and temperature in step A2 are 1-3h and 60-80°C respectively, and the temperature of the low-temperature drying is 40-45°C.

Images